#USA #PTC Therapeutics #stock options #RSUs #Warren, New Jersey

PTC Therapeutics Inducement Grants Overview

In a significant move to strengthen its workforce, PTC Therapeutics, Inc. (NASDAQ: PTCT) announced the approval of stock options and restricted stock units (RSUs) for new employees. On March 24, 2025, the company allocated non-statutory stock options amounting to 12,000 shares of common stock and additionally, 28,220 RSUs to a total of 35 new hires. This initiative is aligned with the Nasdaq Listing Rule 5635(c)(4), which permits such inducement grants to attract talent to the company.

Details of the Grants

The inducement grants, authorized by the Compensation Committee of PTC Therapeutics, serve as a financial incentive for new employees to join and contribute to the company's mission. The stock options come with an exercise price set at $57.03 per share, reflecting the closing price of the company's common stock on the grant date. The options are set with a 10-year term, featuring a vesting schedule over four years. Specifically, 25% of the awarded shares will vest on the first anniversary of the new hire's start date, with the remaining shares vesting quarterly at a rate of 6.25% every three months thereafter. This gradual vesting approach is designed to incentivize long-term commitment from the employees.

For the RSUs, these will also follow a four-year vesting schedule, with 25% of shares vesting each year on the anniversary of the employee’s joining date, contingent upon the employee maintaining their service during the vesting period.

PTC Therapeutics' Commitment to its Workforce

PTC Therapeutics has established itself as a global biopharmaceutical leader focused on developing clinically differentiated medicines for individuals with rare disorders. The company's dedication to providing groundbreaking treatments underscores its investment in a robust and diversified product pipeline.

By offering competitive compensation packages that include stock options and RSUs, PTC aims to attract highly qualified professionals who are committed to furthering the company’s innovative strategies. This approach not only enhances employee satisfaction and retention but also aligns individual contributions with the company's broader goals of delivering transformative healthcare solutions.

As the healthcare and biopharmaceutical sectors continue to evolve, PTC Therapeutics recognizes the importance of recruiting and retaining top talent to drive its mission forward. The inducement grants exemplify the company's strategy of combining financial incentives with a strong organizational culture that fosters growth and innovation.

About PTC Therapeutics, Inc.

PTC Therapeutics is a renowned biopharmaceutical company committed to the discovery and commercialization of medicines that fulfill unmet medical needs, particularly for patients suffering from rare diseases. With a strong emphasis on scientific expertise and global outreach, PTC Therapeutics is dedicated to ensuring access to high-quality treatments for those who need them the most. To explore more about the company's offerings and innovative therapies, visit www.ptcbio.com and follow PTC on social media platforms like Facebook, X, and LinkedIn.

Conclusion

The recent inducement grants by PTC Therapeutics illustrate the company’s proactive stance in enhancing its workforce's morale and investment in future innovation. With a focus on employee stability and satisfaction through well-structured compensation models, PTC Therapeutics sets a commendable example in the industry, aiming to not only meet current healthcare challenges but also to pioneer advancements in patient care.